1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,800 | 0,835 | 15:13 | |
| 0,800 | 0,835 | 13:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.02. | MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 611 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 10.02. | Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 559 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 02.02. | NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres | 437 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 20.01. | DealFlow Events: NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference | 886 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 13.01. | NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 | 705 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 01.12.25 | NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles | 658 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | NANOVIRICIDES, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.11.25 | NanoViricides GAAP EPS of -$0.10 | 16 | Seeking Alpha | ||
| 17.11.25 | NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | 426 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter... ► Artikel lesen | |
| 14.11.25 | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 | 660 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 12.11.25 | NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 691 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement... ► Artikel lesen | |
| 11.11.25 | NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 669 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a... ► Artikel lesen | |
| 10.11.25 | NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo | 689 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of... ► Artikel lesen | |
| 05.11.25 | NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT | 657 | ACCESS Newswire | NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company")... ► Artikel lesen | |
| 03.11.25 | NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd | 568 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 29.10.25 | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 712 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| 27.10.25 | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 711 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 22.10.25 | In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides | 621 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 21,950 | +2,57 % | EQS-News: Formycon AG: Formycon gibt positive klinische Daten für den Keytruda-Biosimilar-Kandidaten FYB206 (Pembrolizumab) bekannt | EQS-News: Formycon AG
/ Schlagwort(e): Studienergebnisse/Studie
Formycon gibt positive klinische Daten für den Keytruda-Biosimilar-Kandidaten FYB206 (Pembrolizumab) bekannt
25.02.2026... ► Artikel lesen | |
| ONTO INNOVATION | 181,00 | +1,12 % | ONTO INNOVATION INC. - 10-K, Annual Report | ||
| VEECO INSTRUMENTS | 28,200 | +0,71 % | Veeco books multi-system Lumina and Spector orders for InP datacom laser manufacturing | ||
| CANATU | 7,660 | +0,79 % | Canatu Oyj: Canatu's Financial Statements Bulletin 2025 | Canatu Plc Company announcement 3 March 2026 at 9:00 a.m. EET
Canatu's Financial Statements Bulletin 2025
This is a summary of Canatu Plc's Financial Statements Bulletin for the year 2025. The complete... ► Artikel lesen | |
| ZENTEK | 0,515 | -4,63 % | Zentek Ltd.: Zentek Announces Pilot Evaluation Program with Quality Filters Inc. | GUELPH, ON / ACCESS Newswire / March 4, 2026 / Zentek Ltd. ("Zentek" or the "Company") (TSXV:ZEN)(NASDAQ:ZTEK) is pleased to announce the initiation of a pilot evaluation program with Quality Filters... ► Artikel lesen | |
| RIBER | 6,200 | +2,48 % | RIBER: 2025 performance driven by production systems and the rollout of ROSIE | 2025 performance driven by production systems and the rollout of ROSIE Revenues of €40.3 million in line with guidanceOrder book at December 31, 2025: €26.9 million (+24%) Bezons (France), February... ► Artikel lesen | |
| DOTZ NANO | 0,022 | 0,00 % | DOTZ NANO LIMITED: Notice of Annual General Meeting/Proxy Form | ||
| KOPIN | 2,000 | +2,56 % | Kopin Corporation: Michael Murray, Kopin's CEO to Present at THEON International's Capital Markets Day (CMD) on November 6, 2025 | Kopin Corporation (NASDAQ: KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,340 | +4,94 % | FendX Technologies Inc.: FendX and Aquaox Enter into Collaboration Agreement to Pursue Innovation in Eco-Friendly Antimicrobial Agents | Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company... ► Artikel lesen | |
| OBDUCAT | 0,003 | -23,81 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 3,460 | +0,58 % | ACACIA RESEARCH CORP - 8-K, Current Report | ||
| ADVANCE ZINCTEK | 0,515 | 0,00 % | ADVANCE ZINCTEK LIMITED: Half Yearly Report and Accounts | ||
| LAMPETIA | 0,094 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GOMSPACE | 1,716 | +6,58 % | GomSpace Group AB: GomSpace signs 7.6 MEUR contract with VirtuaLabs for a satellite cluster for Radio Frequency space-based environment monitoring | GomSpace has signed a contract valued at 7.6 MEUR (81.5 MSEK) with VirtuaLabs, an Italy-based company specialized in Satellite Payloads, to deliver a cluster of satellites supporting space-based Radio... ► Artikel lesen | |
| REGION GROUP | 1,315 | -1,39 % | REGION GROUP: Update - Notification of buy-back - RGN |
Das Unternehmen NANOVIRICIDES INC kann der Branche Nanotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,040 (+4,94 %) liegt der Kurs bei 0,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.